Galderma’s $1.5 Billion Skincare Deal. Somebody Please Show Me the Synergy Spreadsheet.

The skincare business promises to improve what we see in the mirror. Acquisition accounting occasionally tries something similar with a financial result.

I’d like to know which improvements survive when the flattering adjustments come off.

Galderma’s ZO Skin Health acquisition is an interesting strategic move, and I can see why a buyer with established commercial capabilities would consider another physician-dispensed brand. There may be real value in combining complementary offerings.

My interest is in the distance between “complementary” and the money.

That distance contains financing, customer retention, integration work and people expected to deliver benefits while continuing their ordinary jobs. It rarely fits neatly into the arrows on the deal presentation.

For the Galderma ZO Skin Health acquisition, I’d build the financial case around what must happen after closing. A signed agreement can establish the opportunity. It cannot deliver the synergies on behalf of the employees who will be asked to find them.

Galderma ZO Skin Health acquisition: the agreement isn’t a closing

On October 14, 2026, Galderma announced an agreement to acquire 100% of ZO Skin Health for $1.5 billion enterprise value in an all-cash transaction, subject to customary adjustments.

ZO recorded approximately $330 million of net sales in the twelve months to June 2026. Galderma says financing will combine existing cash and bank financing. Closing is expected in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary conditions.

The company expects the deal to be core EPS neutral in the first full year following closing, slightly dilutive to group core EBITDA margin in 2027, and to reach a margin broadly comparable with the group average from 2028.

The original Galderma announcement is here.

Those are disclosed expectations. The acquisition has been agreed, not reported as completed. The valuation, financing and synergy illustrations below are hypothetical and do not fill gaps in the company’s disclosures.

Enterprise value needs a bridge to the payment

Enterprise value measures the value assigned to the operating business under a specified convention. Equity consideration reflects what is paid for the shares after relevant adjustments.

I’d require the bridge before using the headline amount as either the shareholder payment or the financing requirement.

First worked example: what the buyer has to fund

For an illustrative transaction, assume $1.5 billion enterprise value, $200 million of target debt and $50 million of target cash. Net debt is $150 million, so simplified equity value is $1.35 billion.

If the buyer pays $1.35 billion for shares and settles $200 million of target debt, gross uses are $1.55 billion. The acquired $50 million of cash reduces the net amount to $1.5 billion, before transaction costs and other adjustments.

Restricted or required operating cash may not be available for that purpose. Working-capital adjustments, debt-like items and contract terms can change the actual reconciliation.

These debt and cash amounts are invented. Galderma’s release doesn’t establish this bridge.

I’d present gross funding needs, cash available and the final purchase-price mechanism separately. Otherwise a deal can arrive at Treasury with a confident enterprise-value headline and an invoice that has brought additional guests.

The revenue multiple is a starting question

Dividing disclosed enterprise value by disclosed trailing sales gives approximately 4.55 times revenue.

That ratio tells me the price relative to sales. It does not tell me whether the transaction is attractive.

In an illustrative sensitivity using $330 million of revenue, a 20% EBITDA margin produces $66 million of EBITDA, implying about 22.7 times EBITDA at $1.5 billion enterprise value.

At 25%, EBITDA becomes $82.5 million and the multiple is about 18.2 times. At 30%, EBITDA is $99 million and the multiple is about 15.2 times.

I am not asserting that any of those margins belongs to ZO. The cited announcement does not provide the target EBITDA needed for that calculation.

The range explains why I wouldn’t announce that 4.55 times sales proves overpayment. Different margins, growth and capital needs produce different economics.

A revenue multiple is a useful way to open the file. It is a poor reason to close it.

Cash conversion can move the valuation again

Two businesses with identical EBITDA can require different amounts of capital expenditure, inventory and receivables. Taxes and ongoing development needs can also differ.

I’d construct a normalized cash-flow bridge before deciding what the earnings stream is worth. I would distinguish necessary recurring commercial investment from a temporary launch campaign, and maintenance investment from expansion.

In a deliberately simple valuation illustration, assume next-year unlevered free cash flow of $75 million, perpetual growth of 2% and a 10% discount rate. Value is $937.5 million: $75 million divided by 8%.

At the same growth and discount rates, $120 million of next-year cash flow supports $1.5 billion.

That is a perpetuity sensitivity, not a valuation of the actual target. It assumes the business is already in a sustainable growth state. A real model would use an explicit forecast, taxes, investment requirements and a defensible terminal value.

The illustration shows the cash flow a price requires under specific assumptions. It doesn’t prove what ZO will generate or what Galderma can add.

The strategy can be convincing without replacing the model

An acquirer may have distribution, expertise or infrastructure that makes a target more valuable in its hands. Those advantages can justify paying more than a standalone buyer.

I’d try to identify the mechanism. Does the buyer reach customers the target couldn’t reach economically? Can it improve product development or commercial productivity? Are there genuinely avoidable duplicated costs?

Then I’d ask what investment is required to realize each benefit. Expansion into a new market can require training, approvals, distribution and customer support. Access to a channel doesn’t make the channel costless.

The target also has assets we should be careful not to damage: relationships, specialist knowledge, brand identity and effective routines. Integration can remove duplication or destroy what the buyer wanted.

My discussion of why a good business and a good investment are different questions applies directly.

I can understand the strategic rationale and still want the economic case. Liking the business is useful. Paying the right price requires another conversation.

Revenue synergies have a longer journey than cost savings

A cost synergy might remove a duplicated expense, subject to contracts, severance and replacement needs. Revenue synergy requires somebody to buy something they otherwise wouldn’t have bought.

That difference belongs in the risk and timing assumptions.

I’d build revenue benefits from accounts, adoption, average realized sales and contribution margin. The model should allow for cannibalization, discounts and extra commercial effort.

Suppose a buyer forecasts $30 million of incremental revenue. If $8 million merely shifts from an existing group brand, genuinely incremental group revenue is $22 million before other effects.

At a 35% contribution margin, $22 million contributes $7.7 million, rather than the $10.5 million implied by the full $30 million.

The acquired brand’s sales report could look excellent while group economics disappoint. I’d track the portfolio, not let each brand claim credit for the same customer wallet.

Revenue synergy needs a counterfactual: what would the combined company have sold without the acquisition? Otherwise ordinary growth can get dressed up as deal success.

Second worked example: a synergy that has to pay for itself

Use a separate hypothetical plan with $30 million of genuinely incremental annual revenue at a 35% contribution margin. That creates $10.5 million of contribution.

Add $8 million of recurring cost efficiencies. Subtract $3 million of recurring support expense. Mature incremental EBITDA is $15.5 million.

That number excludes financing, tax, capital expenditure, working capital and one-time integration costs. It is not an amount Galderma has forecast.

I’d ask who owns the revenue and who owns the cost removals. “The combined platform” cannot attend a performance review or sign a supplier termination.

I would also assign dependencies. A distribution benefit may require systems work before sales can begin. A cost reduction may require a lease to expire.

The sponsor should explain which benefits are additive and which overlap. Consolidated reporting is not allowed to count a removed expense once under procurement and again under overhead.

A synergy with no accountable owner is an aspiration with a very impressive number attached.

The first year can consume the benefit

Assume that hypothetical revenue synergy reaches only $10 million in year one, creating $3.5 million of contribution. Cost efficiencies reach $2 million, while recurring support already costs $3 million.

Recurring incremental EBITDA is only $2.5 million. If $12 million of integration expense is recognized in that year, the modeled total EBITDA impact is negative $9.5 million.

In year two, suppose revenue synergy rises to $20 million, cost efficiencies to $5 million, and support remains $3 million. Incremental EBITDA becomes $9 million.

In year three, the mature plan reaches $15.5 million.

I’d show that ramp instead of presenting the mature run rate as though it begins at closing. The integration team is going to need cash before the commercial plan finishes arriving.

A negative first year may be perfectly rational. Hiding it does not improve the deal; it merely postpones the meeting.

Discount the benefits rather than admiring them

For a simplified cash valuation of that synergy schedule, assume a 25% tax rate, immediate usable tax effects, and no incremental capital expenditure or working-capital requirement. Those are generous assumptions that would need scrutiny in practice.

Year-one after-tax flow is negative $7.125 million. Year two is positive $6.75 million. From year three onward, assume $11.625 million annually forever with no growth.

At a 10% discount rate, the present value is approximately $95.2 million. The mature perpetuity is valued at the end of year two, then discounted alongside the first two cash flows.

If the entire schedule shifts one year later, its value falls to about $86.5 million, excluding additional delay costs.

This is an isolated synergy illustration, not the value of the target or the acquisition. It also assumes unusually clean cash conversion and perpetual persistence.

Even so, the delay costs roughly $8.7 million of value. “We’ll get there eventually” has a measurable price.

Financing deserves its own downside case

The announcement identifies cash and bank financing but not the assumed debt split or interest rate in my model. I’d avoid inserting a precise financing claim where the disclosure doesn’t supply one.

For a hypothetical $900 million debt-funded portion, a 6% interest rate produces $54 million annual interest. At 7.5%, it produces $67.5 million, an increase of $13.5 million.

I would model maturities, fees, covenants and repayment capacity as well as the rate. Existing cash also has an opportunity cost and may be needed elsewhere.

The unlevered valuation and financing plan need separate treatment. If project cash flows exclude financing and are discounted at WACC, subtracting interest again from those same cash flows would mix methods.

Treasury still needs the actual interest and principal schedule for liquidity. The fact that a valuation model excludes interest doesn’t mean the lender has agreed to do so.

Strategic fit may improve the business. It will not persuade the bank to accept a synergy diagram as the quarterly payment.

EPS neutrality doesn’t establish economic value

A transaction can be EPS neutral or accretive and still earn less than its required return. Funding choices, accounting treatment and the starting earnings base affect the per-share calculation.

I’d compare economic value using cash flows and required returns, while separately reconciling the company-defined core EPS measure. Any exclusions should be understood rather than treated as proof that a cost disappeared.

Imagine spending $1 billion on an asset generating $50 million of sustainable annual after-tax operating profit. If the required return is 10%, the annual capital charge is $100 million. The economic profit is negative $50 million.

Depending on financing and accounting, an EPS presentation might still be attractive. The example is simplified, but the distinction matters.

I’d also ask whether a return calculation includes the purchase premium and relevant acquisition capital. Evaluating only tangible operating assets after buying goodwill can make the return look better than the shareholder investment warrants.

The purchase price deserves to remain in the conversation after accounting has given its components new names.

Integration costs should have an expiration test

I’d budget systems changes, people, contracts, training, inventory transition and other relevant costs by action and month. Then I’d distinguish one-time integration spending from costs that remain to support the business.

Some expenses are called temporary for so long that they qualify as institutional traditions.

If the combined organization needs permanent specialist support, it belongs in recurring economics. If systems changes need repeated maintenance, that maintenance belongs in the mature case.

I’d also capture disruption costs: delayed shipments, staff departures, customer attrition and duplicated work during transition. Some will be difficult to estimate. They should be represented with ranges rather than declared nonexistent.

A project manager should own delivery, and Finance should reconcile cash spending to the business case. The acquisition team should not hand over a mature synergy number and vanish as soon as the closing dinner ends.

The integration budget isn’t an administrative appendix. It is part of the price of making the strategy real.

Compare the acquisition with building and partnering

An acquisition buys an established business, including capabilities that may take years to recreate. It can provide speed and control, while committing substantial capital and integration effort.

Organic expansion may require less upfront capital and permit staged investment. It also carries development risk, a slower commercial ramp and the possibility that the opportunity moves away while we build.

A partnership or licensing arrangement can provide access without buying the entire company. It may surrender margin, control or exclusivity and create dependence on a counterparty.

I’d compare these routes against the same commercial objective. If we need a particular customer channel, buying a whole business may or may not be the best route. If the brand and organization are central, a narrower arrangement may be insufficient.

The capital investment decision should include the cost of waiting as well as the cost of acting.

“Acquisition versus doing nothing” is often an unnecessarily flattering comparison for the acquisition.

Protect the downside that could break the plan

I’d run a case with slower growth, weaker contribution and delayed cost removal. Then I’d test the liquidity consequences alongside value.

Suppose hypothetical mature revenue synergy falls from $30 million to $15 million. At 35%, contribution is $5.25 million. If cost efficiencies reach only $4 million and recurring support remains $3 million, mature incremental EBITDA is $6.25 million.

That’s $9.25 million below the original $15.5 million plan. The integration cost may still arrive in full.

I’d identify what management can change: commercial sequencing, optional investment, service design or integration scope. I’d also state what it cannot readily reverse once the purchase is complete.

A downside scenario needs decisions and funding. My discussion of cash forecasting beyond an arbitrary short horizon is relevant when costs precede benefits by years.

An acquisition can be an attractive long-term choice and a demanding near-term liquidity commitment. I’d like both facts in the approval.

The scorecard should survive the original deal team

I’d preserve the standalone baseline, the original synergy plan and subsequent forecast changes. That lets management distinguish acquired earnings, underlying market growth and actual integration benefits.

Each material benefit needs a named owner, a delivery date, a metric and a cost to achieve. The baseline should be agreed before the result becomes politically valuable.

I’d measure customer retention and group contribution alongside revenue. I’d measure net cost removal after replacement expense. I would reconcile one-time cash spending and ongoing capital needs.

When a benefit misses, the response should follow the cause. A delay may call for sequencing changes. A weak underlying thesis may call for reallocation.

The principle behind reviewing funding without sacred cows remains useful after a transaction. Closing a deal doesn’t make every subsequent investment mandatory.

The model should keep learning. It should not spend the next three years protecting the dignity of the original announcement.

My conclusion: make the combination earn the premium

I can see a credible strategic reason for Galderma to consider ZO Skin Health. The public disclosure alone does not establish whether the price is too high, too low or exactly right.

My opinion is that Finance should make the deal earn its case through cash, timing and accountable delivery. I’d support a premium when the buyer can substantiate advantages unavailable through cheaper alternatives.

I would challenge a case that treats revenue multiples as valuation, mature synergies as first-year earnings or EPS neutrality as proof of value creation.

The approval should include what happens if growth arrives later and integration costs remain stubbornly on time. Costs are often punctual like that.

Before the next acquisition review, ask who owns the largest synergy and which monthly cash movements show it becoming real.

If the answer is “the combined organization,” keep asking. We are buying a business, not commissioning a motivational poster. Somebody has to deliver the number after the deal stops being news.

Sources and calculation notes

Deal disclosures come from Galderma’s October 14, 2026 acquisition announcement. The revenue multiple uses disclosed enterprise value and trailing sales. All target margins, debt balances, financing rates, valuation assumptions and synergy schedules here are hypothetical. They are not Galderma guidance, estimates of ZO’s undisclosed earnings or a fairness opinion.